Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16754029 | 1.00 | MEN1 (0.51) | MEN1KMT2ACA12CA9CA7 | |
| SCHEMBL7229148 | 0.89 | CA12 (0.49) | MEN1KMT2ACA12CA9CA7 | |
| SCHEMBL8142297 | 0.86 | MEN1 (0.43) | MEN1KMT2ACA12CA9CA7 | |
| SCHEMBL7726567 | 0.86 | MEN1 (0.43) | MEN1KMT2ACA12CA9CA7 | |
| SCHEMBL7728941 | 0.86 | MEN1 (0.43) | MEN1KMT2ACA12CA9CA7 | |
| SCHEMBL8711997 | 0.86 | PPARG (0.44) | KMT2ACA12CA9CA2CTRB1 | |
| SCHEMBL8711993 | 0.86 | PPARG (0.44) | KMT2ACA12CA9CA2CTRB1 | |
| SCHEMBL7307706 | 0.85 | SRR (0.56) | PPARGPPARASRR | |
| SCHEMBL7307715 | 0.85 | SRR (0.56) | PPARGPPARASRR | |
| SCHEMBL7321720 | 0.85 | SRR (0.56) | PPARGPPARASRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206854-B | FXIa inhibitor and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-02-24 | — | — | CN | disclosed |
| CN-114206854-A | FXIa inhibitor and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3138839-B1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| CN-105829298-B | A kind of pyridone or pyrimidone derivatives, and its preparation method and application | 四川海思科制药有限公司 | 2019-02-01 | — | — | CN | disclosed |
| US-10174020-B2 | Pyridone or pyrimidone derivative, preparation method therefor and application thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-01-08 | — | — | US | disclosed |
| US-10174020-B2 | Pyridone or pyrimidone derivative, preparation method therefor and application thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-01-08 | — | — | US | disclosed |
| EP-3138839-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| EP-3138839-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| US-20170029423-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20170029423-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20060052348-A1 | Oxazolo-naphthyl acids | WYETH (US) | 2006-03-09 | — | — | US | disclosed |
| WO-2006023866-A2 | THIAZOLO-NAPHTHYL ACIDS AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | WYETH (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006023865-A1 | OXAZOLO-NAPHTHYL ACIDS AS PLAMINOGEN ACTIVATOR INHIBTOR TYPE-1 (PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES | WYETH (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006023864-A1 | PYRROLO-NAPHTHYL ACIDS AS PAI-1 INHIBITORS | WYETH (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060020003-A1 | Biphenyloxy-acids | WYETH (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2005030702-A1 | BIPHENYLOXY-ACIDS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1397341-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6589970-B2 | This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: | WYETH | 2003-07-08 | — | — | US | disclosed |
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-03-06 | — | — | US | disclosed |
| WO-2003000649-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052348-A1 | Oxazolo-naphthyl acids | SERPINE1, SERPINB1, SERPINC1 | MEN1 2828/4885KMT2A 4416/4885CA12 2569/4885 |
| US-20060020003-A1 | Biphenyloxy-acids | AHR, ARNT, NR1H4 | MEN1 3931/4885KMT2A 894/4885CA12 3136/4885 |
| US-10174020-B2 | Pyridone or pyrimidone derivative, preparation method therefor and application thereof | TYMP, DHFR, TYMS | MEN1 882/4885KMT2A 3474/4885CA12 4874/4885 |
| US-20170029423-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TYMP, DHFR, TYMS | MEN1 882/4885KMT2A 3474/4885CA12 4874/4885 |
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | SERPINC1, F11, SERPINE1 | MEN1 2764/4885KMT2A 3476/4885CA12 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.